Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis. Issue 9 (9th June 2017)

• Record Type: Journal Article
• Authors: Bair, Steven M.; Strelec, Lauren; Nagle, Sarah J.; Nasta, Sunita D.; Landsburg, Daniel J.; Mato, Anthony R.; Loren, Alison W.; Schuster, Stephen J.; Stadtmauer, Edward A.; Svoboda, Jakub
• Is Part Of: American journal of hematology. Volume 92:Issue 9(2017:Sep.)
• Page Start: 879
• Page End: 884
• Publication Date: 2017-06-09
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.24792
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstract: Patients with relapsed/refractory Hodgkin lymphoma (RR‐HL) who progress or relapse following autologous stem cell transplantation (ASCT) have historically had a poor prognosis. Several novel agents, particularly brentuximab vedotin, have shown efficacy in this setting. However, there remains a paucity of data characterizing outcomes outside of clinical trials and how these novel agents have impacted prognosis in general population of patients with RR‐HL. Here, we conducted a retrospective analysis to evaluate outcomes in 87 patients with RR‐HL with relapse post‐ASCT. Treatment with novel agents (including brentuximab vedotin) was associated with significant improvement in median overall survival (OS) compared to patients who did not receive novel agents (85.6 vs 17.1 months; P < .001). Additional factors associated with improved OS in univariate analysis include treatment with radiation therapy post‐ASCT (34.1 vs 17.0 months; P = .015), chemosensitivity (i.e., relapsed compared to primary refractory disease; 51.8 vs 25.6 months; p = 0.013), initial response to ASCT (i.e., CR/PR compared to SD/PD; 46.1 vs 20.4 months; P = .011), and transplantation in 2010 and later compared to prior to 2010 (not reached vs 24.5 months; P = .025). The current study demonstrates markedly improved OS in RR‐HL patients treated with novel therapeutics and lends "real world" credence to the role of these agents in improving outcomes in the current era.